The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cluff LE. Effects of lipopolysaccharides (endotoxins) on susceptibility to infection. J Infect Dis 1970; 122: 205.
Kimball HR, Williams TW, Wolff SM. Effect of bacterial endotoxin on experimental fungal infections. J Immunol 1968; 100: 24.
Wright LJ, Kimball HR., Wolff SM. Alterations in host responses to experimentalCandida albicans infections by bacterial endotoxin. J immunol 1969; 103: 1276.
Chedid L, Parant M, Parant F, Lefrancier P, Choay J, Lederer E. Enhancement of non-specific immunity toKlebsiella pneumoniae infection by a synthetic immuno-adjuvant (N-acetyl-muramyl-L-alanyl-Disoglutamine) and several analogs. Proc Natl Acad Sci USA 1977; 74: 2089.
Cummings NP, Pabst MJ, Johnston Jr RB. Activation of macrophages for enhanced release of superoxide anion and greater killing ofCandida albicans by injection of muramyl dipeptide. J Exp Med 1980; 152: 1659.
Dinarello CA, Cannon JG, Mier JW, Bernheim HA., LoPreste G, Lynn DL, Love RN, Webb AC, Auron PE, Reuben RC, Rich A, Wolff SM, Putney SD. Multiple biological activities of human recombinant interleukin-1. J Clin Invest 1986; 77: 1734.
Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA, O'Connor JV. Tumor necrosis factor (cachectin) is an endogeneous pyrogen and induces production of interleukin 1. J. Exp Med 1986; 163: 1433.
Van der Meer JWM, Barza M, Wolff SM, Dinarello CA. Low dose recombinant interleukin-1 protects granulocytopenic mice from lethal Gram-negative infection. Proc Natl Acad Sci USA 1988; 85: 1620.
Bakker-Woudenberg IAJM, van den Berg JC, Michel MF. Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally inducedKlebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother 1982; 22: 1042.
Kunst MW, Mattie H, van Furth R. Antibacterial efficacy of cefazolin and cephradine in neutropenic mice. Infection 1979; 7: 30.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard V, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Brit J Cancer 1977; 35: 1.
Ozaki Y, Ohashi T, Minami A, Nakamura S-I. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-la. Infect Immun 1987; 55: 1436.
Czuprynski CJ, Brown JF. Recombinant interleukin-la enhancement of nonspecific antibacterial resistance. Infect Immun 1987; 55: 2061.
Kampschmidt RF, Pulliam LA. Stimulation of antimicrobial activity in the rat with leucocytic endogenous mediator. J. Reticuloendothel Soc 1975; 17: 162.
Van't Wout J, Van der Meer JWM, Barza M, Dinarello CA. Protection of neutropenic mice from lethalCandida albicans infection by recombinant interleukin 1. Eur J Immunol 1988; 18: 1143–16.
Parant M, Parant F, Vinit M-A, Chedid L. Action protectrice du ‘tumor necrosis factor’ (TNF) obtenu par recombinaison génétique conter l'infection expérimentale bactérienne ou fongique. CR Acad Sc Paris 1987; 304: 111, I.
Parant M. Role of TNF in nonspecific stimulation of the mouse resistance to infections. In Bonavide B., ed. Tumor necrosis factor/cachectin, lymphotoxin and related cytokines. Basel: Karger, in press.
Taverne J, Travernier J, Fiers W, Playfair JHL. Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro. Clin Exp Immunol 1987; 67: 1.
Smith RA, Kirstein M, Fiers W, Baglioni C. Species specificity of human and murine tumor necrosis factor. A comparative study of tumor necrosis factor receptors. J Biol Chem 1986; 261: 14871.
Gustilo EJAK, Baeder W, Freundlich B. Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin 1 and tumor necrosis factor. J Immunol 1987; 138: 3812.
Okusawa S, Gelfand JA, Ikejima T, Conolly RT, Dinarello CA. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162.
White CW, Ghezzi P, Dinarello CA, Caldwell SA, McMurty IF, Repine JE. Recombinant tumor necrosis factor/cachectin and interleukin-I pretreatment decreases lung oxidized glutathione accumulation, lung injury and mortality in rats exposed to hyperoxia. J Clin Invest 1987; 79: 1863.
Mochizuki DY, Eisenman JR, Conlon PJ, Larsen AD, Tushinsky RJ. Interleukin I regulates hematopoietic activity, a role previously ascribed to hematopoietin 1. Proc Natl Acad Sci USA 1987; 84: 5267.
Moore MAS, Warren DJ. Synergy of interleukin-1 and granulocyte colony-stimulating factor: In vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci USA 1987; 84: 7134.
Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide binding acute phase reactant from rabbit serum. In: Peeters H, ed. Protides of the biological fluids, Vol. 36. New York, NY: Pergamon Press, 1986; 501.
Riveau GR, Novitsky TJ, Roslansky PF, Dinarello CA, Warren HS. Role of interleukin-I in augmenting serum neutralization of bacterial lipopolysaccharide. J Clin Microbiol 1987; 25: 889.
Beutler B, Milsark IW, Cerami A. Passive immunization against Cachectin/Tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869.
Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1988; 330: 662.